Key facts
- Notable investors include Entrée Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Undecimal Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Undecimal Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Undecimal Bio
Developer of a DNA-encoded library platform designed to discover RNA delivery molecules systematically. This company is currently operating in Stealth mode.
- Sector
- Business Products and Services (B2B)
- HQ
- Ramat Gan, Israel
- Founded
- 2025
- Website
- undecimalbio.com/
- Ownership
- Privately Held (backing)
Undecimal Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Undecimal Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Undecimal Bio in its N-PORT filings yet. We sweep new filings monthly.